[go: up one dir, main page]

AR062941A1 - Compuestos para el tratamiento de desordenes metabolicos - Google Patents

Compuestos para el tratamiento de desordenes metabolicos

Info

Publication number
AR062941A1
AR062941A1 ARP070104184A ARP070104184A AR062941A1 AR 062941 A1 AR062941 A1 AR 062941A1 AR P070104184 A ARP070104184 A AR P070104184A AR P070104184 A ARP070104184 A AR P070104184A AR 062941 A1 AR062941 A1 AR 062941A1
Authority
AR
Argentina
Prior art keywords
compounds
alkyl
treatment
aryl
metabolic disorders
Prior art date
Application number
ARP070104184A
Other languages
English (en)
Original Assignee
Nichols David John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nichols David John filed Critical Nichols David John
Publication of AR062941A1 publication Critical patent/AR062941A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos que resultan utiles para tratamiento de desordenes metabolicos relacionados con la resistencia a la insulina o a la hiperglucemia. Asimismo se relaciona a un proceso para la elaboracion de compuestos de la formula (1) y las composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula general (1), en donde Ar es una porcion de quinolina o isoquinolina que se encuentra sustituida o no sustituida; B es -O-, -S-, o -NH-; R1 es hidrogeno o S(O)2R4; R2 es S(O)2R4, C(O)OR5, o C(O)(CH2)n-C(O)OR6; R3 es halogeno, ciano, (CO)OR7, o C(O)NR8R9; R4 es arilo; R5 es alquilo C1-6 o arilo; R6 es hidrogeno, alquilo C1-4 o arilo; R7 es H o alquilo C1-4; R8 y R9 son independientemente hidrogeno o alquilo C1-6; n es un entero de 1-3; y una sal o solvato farmacéuticamente aceptable de los mismos.
ARP070104184A 2006-09-21 2007-09-21 Compuestos para el tratamiento de desordenes metabolicos AR062941A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US87567206P 2006-12-18 2006-12-18

Publications (1)

Publication Number Publication Date
AR062941A1 true AR062941A1 (es) 2008-12-17

Family

ID=39048032

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070104183A AR062940A1 (es) 2006-09-21 2007-09-21 Compuestos para el tratamiento de desordenes metabolicos
ARP070104184A AR062941A1 (es) 2006-09-21 2007-09-21 Compuestos para el tratamiento de desordenes metabolicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070104183A AR062940A1 (es) 2006-09-21 2007-09-21 Compuestos para el tratamiento de desordenes metabolicos

Country Status (19)

Country Link
US (5) US8030324B2 (es)
EP (2) EP2094663B1 (es)
JP (2) JP5331953B2 (es)
KR (2) KR20090075827A (es)
AR (2) AR062940A1 (es)
AT (1) ATE496890T1 (es)
AU (2) AU2007298540B2 (es)
BR (2) BRPI0717106A2 (es)
CA (2) CA2663901A1 (es)
DE (1) DE602007012299D1 (es)
DK (1) DK2094663T3 (es)
IL (2) IL197694A0 (es)
MX (2) MX2009002905A (es)
NZ (2) NZ576197A (es)
PL (1) PL2094663T3 (es)
PT (1) PT2094663E (es)
RU (2) RU2448093C2 (es)
TW (2) TW200820970A (es)
WO (2) WO2008035306A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
AU2014300673B2 (en) 2013-06-27 2017-12-14 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EE200100558A (et) * 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL147308A0 (en) * 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
ATE327984T1 (de) * 2000-06-28 2006-06-15 Amgen Inc Benzothiazolyl ppar-gamma modulatoren
WO2004111031A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
ZA200700811B (en) * 2004-08-06 2008-10-29 Otsuka Pharma Co Ltd Aromatic compound
CA2582276C (en) * 2004-10-04 2011-09-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes

Also Published As

Publication number Publication date
US8349862B2 (en) 2013-01-08
JP5331953B2 (ja) 2013-10-30
AU2007298540B2 (en) 2013-02-21
KR20090075827A (ko) 2009-07-09
DE602007012299D1 (de) 2011-03-10
AU2007298539B2 (en) 2013-05-02
EP2094687A1 (en) 2009-09-02
US8269010B2 (en) 2012-09-18
WO2008035305A2 (en) 2008-03-27
IL197695A0 (en) 2009-12-24
RU2009114544A (ru) 2010-10-27
KR20090074775A (ko) 2009-07-07
US20100022554A1 (en) 2010-01-28
AU2007298540A1 (en) 2008-03-27
US20130040988A1 (en) 2013-02-14
JP2010504321A (ja) 2010-02-12
JP2010504322A (ja) 2010-02-12
CA2663901A1 (en) 2008-03-27
US20110312970A1 (en) 2011-12-22
NZ576196A (en) 2011-12-22
EP2094663A2 (en) 2009-09-02
CA2663943A1 (en) 2008-03-27
US20120309786A1 (en) 2012-12-06
TW200820970A (en) 2008-05-16
MX2009002906A (es) 2009-06-30
IL197694A0 (en) 2009-12-24
ATE496890T1 (de) 2011-02-15
WO2008035306A1 (en) 2008-03-27
BRPI0717106A2 (pt) 2013-10-08
PL2094663T3 (pl) 2011-07-29
EP2094663B1 (en) 2011-01-26
NZ576197A (en) 2011-12-22
US20090247574A1 (en) 2009-10-01
US8030324B2 (en) 2011-10-04
PT2094663E (pt) 2011-04-19
BRPI0718510A2 (pt) 2013-11-19
WO2008035305A8 (en) 2009-03-12
RU2448093C2 (ru) 2012-04-20
DK2094663T3 (da) 2011-04-26
AR062940A1 (es) 2008-12-17
TW200817364A (en) 2008-04-16
WO2008035305A3 (en) 2008-06-12
AU2007298539A1 (en) 2008-03-27
MX2009002905A (es) 2009-06-19
RU2009114545A (ru) 2010-10-27
RU2460729C2 (ru) 2012-09-10

Similar Documents

Publication Publication Date Title
AR062941A1 (es) Compuestos para el tratamiento de desordenes metabolicos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
PE20091834A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona tiofenilo-sustituida como inhibidores de bace-1 y composiciones que los contienen
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR074128A1 (es) Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
BRPI0513932A (pt) derivados de indol-2-carboxamidina como antagonistas de receptores de nmda
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
RU2008129623A (ru) Ингибиторы ccr9 активности
BRPI0811245A2 (pt) Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto.
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
AR043186A1 (es) Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende
ATE452636T1 (de) 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen
PE20242216A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
RU2013110377A (ru) Новые производные 6,7-двузамещенного изохинолина и их применение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal